BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37071594)

  • 1. Abl kinase-mediated FUS Tyr526 phosphorylation alters nucleocytoplasmic FUS localization in FTLD-FUS.
    Motaln H; Čerček U; Yamoah A; Tripathi P; Aronica E; Goswami A; Rogelj B
    Brain; 2023 Oct; 146(10):4088-4104. PubMed ID: 37071594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FUS is phosphorylated by DNA-PK and accumulates in the cytoplasm after DNA damage.
    Deng Q; Holler CJ; Taylor G; Hudson KF; Watkins W; Gearing M; Ito D; Murray ME; Dickson DW; Seyfried NT; Kukar T
    J Neurosci; 2014 Jun; 34(23):7802-13. PubMed ID: 24899704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
    Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
    Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
    Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
    Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
    Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
    Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Abl Regulates the Pathological Deposition of TDP-43 via Tyrosine 43 Phosphorylation.
    Lee S; Ryu HG; Kweon SH; Kim H; Park H; Lee KH; Jang SM; Na CH; Kim S; Ko HS
    Cells; 2022 Dec; 11(24):. PubMed ID: 36552734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import.
    Darovic S; Prpar Mihevc S; Župunski V; Gunčar G; Štalekar M; Lee YB; Shaw CE; Rogelj B
    J Cell Sci; 2015 Nov; 128(22):4151-9. PubMed ID: 26403203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).
    Bentmann E; Neumann M; Tahirovic S; Rodde R; Dormann D; Haass C
    J Biol Chem; 2012 Jun; 287(27):23079-94. PubMed ID: 22563080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
    Ito D; Suzuki N
    Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired nuclear transport induced by juvenile ALS causing P525L mutation in NLS domain of FUS: A molecular mechanistic study.
    Basu S; Rajendra KC; Alagar S; Bahadur RP
    Biochim Biophys Acta Proteins Proteom; 2022 Apr; 1870(4):140766. PubMed ID: 35134572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
    Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
    Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frontotemporal lobar degeneration and amyotrophic lateral sclerosis: molecular similarities and differences.
    Neumann M
    Rev Neurol (Paris); 2013 Oct; 169(10):793-8. PubMed ID: 24011641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Conjoint pathological cascades mediated by RNA-binding proteins, TDP-43, FUS and ataxin-2].
    Ito D
    Rinsho Shinkeigaku; 2012; 52(11):1221-3. PubMed ID: 23196570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered mRNP granule dynamics in FTLD pathogenesis.
    Bowden HA; Dormann D
    J Neurochem; 2016 Aug; 138 Suppl 1():112-33. PubMed ID: 26938019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.
    Suárez-Calvet M; Neumann M; Arzberger T; Abou-Ajram C; Funk E; Hartmann H; Edbauer D; Kremmer E; Göbl C; Resch M; Bourgeois B; Madl T; Reber S; Jutzi D; Ruepp MD; Mackenzie IR; Ansorge O; Dormann D; Haass C
    Acta Neuropathol; 2016 Apr; 131(4):587-604. PubMed ID: 26895297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration.
    Dormann D; Haass C
    Mol Cell Neurosci; 2013 Sep; 56():475-86. PubMed ID: 23557964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
    Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
    Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting RACK1 to alleviate TDP-43 and FUS proteinopathy-mediated suppression of protein translation and neurodegeneration.
    Zhao B; Cowan CM; Coutts JA; Christy DD; Saraph A; Hsueh SCC; Plotkin SS; Mackenzie IR; Kaplan JM; Cashman NR
    Acta Neuropathol Commun; 2023 Dec; 11(1):200. PubMed ID: 38111057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import.
    Dormann D; Rodde R; Edbauer D; Bentmann E; Fischer I; Hruscha A; Than ME; Mackenzie IR; Capell A; Schmid B; Neumann M; Haass C
    EMBO J; 2010 Aug; 29(16):2841-57. PubMed ID: 20606625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.